Skip to main content
. 2021 Mar 9;9:656693. doi: 10.3389/fcell.2021.656693

FIGURE 3.

FIGURE 3

Patients’ DFS and OS for the p-JNK expression, by molecular subtypes. (A) Patients’ DFS by molecular subtypes, assessed by the Kaplan-Meier analysis. (B) Patients’ OS by molecular subtypes, assessed by the Kaplan-Meier analysis. (C) Patients’ DFS by Luminal A subtype, assessed by the Kaplan-Meier analysis. (D) Patients’ OS by Luminal A subtype, assessed by the Kaplan-Meier analysis. (E) Patients’ DFS by Luminal B subtype, assessed by the Kaplan-Meier analysis. (F) Patients’ OS by Luminal B subtype, assessed by the Kaplan-Meier analysis. (G) Patients’ DFS by HER2-enriched subtype, assessed by the Kaplan-Meier analysis. (H) Patients’ OS by HER2-enriched subtype, assessed by the Kaplan-Meier analysis. (I) Patients’ DFS by triple-negative subtype, assessed by the Kaplan-Meier analysis. (J) Patients’ OS by triple-negative subtype, assessed by the Kaplan-Meier analysis.